More than 30 percent of adults worldwide carry a diagnosis of metabolic dysfunction-associated steatotic liver disease, which researchers often shorten to MASLD. The condition is not simply a liver problem. A review published in Chronic Diseases and Translational Medicine describes it as a systemic cardiometabolic disorder, meaning it touches multiple organ systems at once. Crucially, the review notes that cardiovascular disease is the leading cause of death among people who have MASLD, not liver failure.
That overlap between liver damage and heart risk has pushed researchers toward a question: is there a single intervention that could address both at the same time? The review focuses on a class of peptides called glucagon-like peptide-1 receptor agonists, or GLP-1 receptor agonists, and surveys the mechanistic, randomized trial, and real-world evidence that has built up around them in the context of MASLD and its more severe form, metabolic dysfunction-associated steatohepatitis, abbreviated MASH.
The article below unpacks what the review found, why the liver-heart connection matters, and what the remaining gaps in the research still look like.
The liver-heart axis explained
The review introduces the idea of a liver-heart axis to explain why damage in one organ tends to accelerate damage in the other. Fat accumulation in liver cells, known as hepatic steatosis, drives a cascade of metabolic disruptions. Insulin resistance worsens, inflammatory signals circulate in the bloodstream, and atherogenic lipoproteins, the kind associated with plaque buildup in arteries, rise. The liver is both a contributor to and a target of these processes.
From a research standpoint, this means treating only the liver or only the cardiovascular system may miss the larger picture. The review argues that an intervention capable of acting on both simultaneously would represent a meaningful advance. GLP-1 receptor agonists became the subject of intensive study partly because early cardiovascular outcome trials, conducted in people with type 2 diabetes, showed reductions in major adverse cardiovascular events that appeared to be partly independent of blood-glucose lowering alone.
What biopsy-based liver trials measured
The most rigorous way to assess liver disease progression is through a biopsy, a small tissue sample examined under a microscope. The review summarizes several biopsy-based randomized trials that enrolled people with confirmed MASH.
In the LEAN trial, researchers studied liraglutide against placebo. They found that 39 percent of participants in the liraglutide group achieved steatohepatitis resolution without fibrosis worsening, compared with 9 percent in the placebo group. Fibrosis refers to the buildup of scar tissue in the liver, and preventing its progression is considered a key goal because advanced fibrosis is linked to worse long-term outcomes.
A phase-2 trial of semaglutide showed dose-dependent results, meaning higher doses corresponded to higher rates of resolution. The top dose reached 59 percent resolution versus 17 percent with placebo. More recently, an interim analysis of a larger semaglutide trial in people with stage 2 or 3 fibrosis reported that 62.9 percent of participants achieved MASH resolution without fibrosis worsening, compared to 34.3 percent on placebo. Fibrosis improvement of at least one stage was seen in 36.8 percent versus 22.4 percent.
The review also covers the SYNERGY-NASH trial, which examined tirzepatide, a dual receptor agonist that targets both GLP-1 and glucose-dependent insulinotropic polypeptide receptors. MASH resolution rates in that trial ranged from 44 to 62 percent depending on dose, compared to 10 percent with placebo, and up to 51 percent of participants showed fibrosis improvement versus 30 percent on placebo.
Cardiovascular outcome trial findings
Separate from the liver trials, a series of large cardiovascular outcome trials has evaluated GLP-1 receptor agonists in people with established heart disease or high cardiovascular risk. The review synthesizes results from several of these.
The LEADER trial of liraglutide, the SUSTAIN-6 and SELECT trials of semaglutide, and the REWIND trial of dulaglutide all demonstrated consistent reductions in major adverse cardiovascular events, a composite measure that typically includes heart attack, stroke, and cardiovascular death. The review notes that these reductions were observed across different GLP-1 receptor agonists, suggesting a class-level effect rather than something unique to a single molecule.
The significance for MASLD research is that people living with the condition are disproportionately affected by cardiovascular risk. If a peptide intervention can simultaneously address the liver histology and reduce cardiovascular events, the potential benefit in that population would be compounded.
Proposed biological mechanisms
The review dedicates considerable space to explaining why GLP-1 receptor agonists might produce these effects in both the liver and the cardiovascular system. Several mechanisms have been proposed based on preclinical and clinical data.
First, the peptides appear to reduce hepatic lipogenesis, the process by which the liver manufactures fat. Less fat production means less accumulation in liver cells, and therefore less cellular stress. Related to this, the peptides seem to reduce lipotoxicity, the damage that excess fat causes to liver cells and surrounding tissue.
Second, researchers have observed attenuation of liver inflammation in treated subjects. Inflammation is a driver of the progression from simple steatosis to MASH, so reducing it is considered a mechanistically meaningful endpoint.
Third, the peptides improve insulin sensitivity. Because insulin resistance is central to the metabolic dysfunction that defines MASLD, improving it may address the disease at a foundational level rather than managing only its downstream consequences.
Finally, the review points to gut-brain-liver signaling as an emerging area of interest. GLP-1 receptors are found not only in the pancreas and liver but also in the brain and gut. Modulating this axis appears to affect appetite, nutrient absorption, and possibly inflammatory tone in ways that are still being characterized. Systemically, the peptides also produce reductions in body weight, blood pressure, and atherogenic lipoproteins, all of which contribute to cardiovascular risk reduction.
Populations highlighted in the review
The review identifies subgroups of MASLD patients for whom the evidence currently looks most relevant. These include people with obesity, those with type 2 diabetes, people with advanced fibrosis, and those with a heart failure phenotype. The authors describe GLP-1 receptor agonists as foundational therapies for these groups based on the collective body of evidence.
The framing is important. The review is not claiming universal benefit across all MASLD presentations. Instead, it identifies the subsets where both the liver and cardiovascular data appear to converge most clearly.
Remaining gaps in the research
The review is candid about what the current evidence does not yet answer. Three major gaps are identified.
The first is treatment duration. Most of the biopsy trials ran for 72 weeks or less, and it remains unclear how long someone would need to receive a GLP-1 receptor agonist to achieve durable liver benefit. Fibrosis, in particular, takes years to develop and may take years to reverse in a clinically meaningful way.
The second gap is the durability of fibrosis benefit. Interim analyses and shorter trials can show improvement in fibrosis stage, but whether that improvement is sustained after treatment ends, or whether it continues to improve with longer use, has not been established.
The third gap is effectiveness in cirrhosis, the most advanced stage of liver scarring. Most trials excluded people with cirrhosis or enrolled very few. Whether the mechanisms observed in earlier-stage disease carry over to cirrhosis is an open question requiring dedicated long-term studies.
The review calls for continued follow-up research to fill these gaps before conclusions about long-term benefit can be drawn with confidence.
